This inhibition holds particular relevance for AD treatment, as TSLP and periostin play crucial roles in initiating and sustaining allergic responses, contributing to symptoms such as pruritus, erythema, and skin barrier dysfunction [38, 39], as evidenced in Figs. 2 and 3. The gene discussed is TSLP; the disease is Erythema.